Abstract: In recent years, immunotherapy has become a hot spot in the field of tumor therapy. Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in treating various tumors. However, primary and secondary resistances to immune checkpoint inhibitors are considerable clinical problems. To further improve the efficacy of ICIs and overcome drug resistance, their combined use with angiogenic drugs has been explored in several studies based on the regulatory mechanism of the immune microenvironment. Antiangiogenic drugs combined with immunotherapy have shown significant efficacy and survival benefits in multiple solid tumors. Antiangiogenic therapy remodels the immune microenvironment while normalizing blood vessels. ICIs enhance a host’s anti-tumor immune response by blocking negative immunomodulatory signals and promote vascular normalization. This study reviews basic and clinical research studies of antiangiogenic drugs combined with ICIs for treating solid tumors.